SWP1001 / Stemirna Therap - LARVOL DELTA

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer (clinicaltrials.gov) - P=N/A | N=24 | Recruiting | Sponsor: Stemirna Therapeutics | Unknown status ➔ Recruiting | Trial completion date: Sep 2022 ➔ Dec 2025 | Trial primary completion date: Sep 2020 ➔ Oct 2024

Enrollment open • Metastases • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Stemirna Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=36; Not yet recruiting; Sponsor: Stemirna Therapeutics

Clinical • New P1 trial • Oncology • Solid Tumor